Zaia John A, Forman Stephen J
1Division of Virology, Beckman Research Institute of City of Hope, Duarte, CA; and.
Hematology Am Soc Hematol Educ Program. 2013;2013:389-93. doi: 10.1182/asheducation-2013.1.389.
With the advent of effective antiretroviral therapy, the treatment of patients with HIV-related malignancies, especially lymphoma, has greatly improved, yielding results comparable to those seen in patients with lymphoma unrelated to HIV. The platform of transplantation of hematopoietic stem cells has facilitated studies of genetically modified stem cells engineered to express antiretroviral genes to resist infection by the HIV virus, testing the concept that engraftment of these cells will lead to HIV resistance and elimination of the reservoir of virus in the body. Results in patients with HIV and lymphoma have now led to studies that will test these principles in HIV patients without concomitant malignancy. In addition, in a patient with HIV and acute myeloid leukemia, the success of an allogeneic transplantation from an unrelated donor carrying a mutation in the CCR5 genes has demonstrated that, in principle, such an approach could also lead to cure of patients with HIV. Case studies in HIV patients with leukemia undergoing allogeneic transplantation also suggest that there may be a therapeutic effect on the HIV reservoir that could alter the natural history of HIV in the allogeneic setting.
随着有效抗逆转录病毒疗法的出现,对与HIV相关恶性肿瘤患者,尤其是淋巴瘤患者的治疗有了很大改善,取得的结果与非HIV相关淋巴瘤患者相当。造血干细胞移植平台推动了对经基因改造以表达抗逆转录病毒基因从而抵抗HIV病毒感染的干细胞的研究,验证了这些细胞植入将导致HIV抵抗并消除体内病毒储存库的概念。HIV合并淋巴瘤患者的研究结果现已促使开展相关研究,以在无合并恶性肿瘤的HIV患者中验证这些原理。此外,在一名HIV合并急性髓系白血病患者中,来自携带CCR5基因突变的无关供体的异基因移植成功表明,原则上这种方法也可治愈HIV患者。对接受异基因移植的HIV合并白血病患者的病例研究还表明,对HIV储存库可能存在治疗作用,这可能会改变异基因环境中HIV的自然病程。